Another synthetic STING agonist, MK-1454, demonstrates potent anti-tumour activity in pre-clinical trials and is currently in clinical development, showing encouraging efficacy (Harrington et al., 2018; Chang W. et al., 2022). The gene discussed is STING1; the disease is neoplasm.